European Federation of Pharmaceutical Industries and Associations
EU lobbying footprint — who they meet, and on what. Built only from official disclosures, every meeting cited.
European Federation of Pharmaceutical Industries and Associations has 274 disclosed EU lobbying meetings from 2019-04-23 to 2026-09-18: 186 with the European Commission and 88 with Members of the European Parliament. Source: EU Transparency Register no. 38526121292-88, Commission disclosures and MEP declarations.
Lobbying profile
as declared 2025-12-17- Category
- Trade and business associations
- Legal status
- Non-profit association
- Declared lobbying cost
- €6,000,000
- Lobbying FTEs
- 13.4
- Members
- 12
Files it’s lobbying on
The org's disclosed policy areas, ranked by number of meetings.
Declared fields of interest
Budget · Business and industry · Climate action · Competition · Consumers · Customs · Digital economy and society · Employment and social affairs · Environment · External relations · Humanitarian aid and civil protection · Institutional affairs
At a glance
The officials and MEPs most often met, by disclosed-meeting count.
- Stella Kyriakides18
- Olivér Várhelyi12
- Thierry Breton7
- Maya Matthews5
- Jana Dabbelt5
Disclosed meetings
Newest first, showing the most recent 60 of 274. EC = European Commission, EP = Member of the European Parliament.
- 2026-09-18ECInge Bernaerts · DirectorImplications of competition policy and law enforcement for investment and innovation in the European pharmaceutical sectorsource ↗
- 2026-09-18ECUlla Schwager · Head of UnitImplications of competition policy and law enforcement for investment and innovation in the European pharmaceutical sectorsource ↗
- 2026-09-10ECMaya Matthews · Head of UnitExchange of views on implementation of the HTA Regulationsource ↗
- 2026-09-10ECBonifacio Garcia Porras · Head of UnitPharmaceutical sector and the mechanisms governing public procurement in this sector - typology of cases and submissions that we receive in the context of the implementation of the FSRsource ↗
- 2026-07-08ECOlga Solomon · Head of UnitDiscussion on AMR incentive metrics on Transferable Exclusivity Voucher (TEV) prepared by EFPIA and related aspects of TEVssource ↗
- 2026-07-08ECKarolina Tomaszewska-Boillot · Cabinet of Commissioner Olivér VárhelyiPreventive health and early detectionsource ↗
- 2026-07-02ECMaya Matthews · Head of UnitExchange of views on implementation of the HTA Regulationsource ↗
- 2026-07-02ECPeter Berz · Head of UnitExchange on market accesssource ↗
- 2026-06-30ECPaul Speight · Head of UnitProposed harmonised classification of Talcsource ↗
- 2026-06-25ECMáté Kander · Head of Unitpresentation of the European Federation of Pharmaceutical Industries (EFPIA) and its priorities.source ↗
- 2026-06-25ECIgnacio Iruarrizaga Díez · Head of Unitpresentation of the European Federation of Pharmaceutical Industries (EFPIA) and its priorities.source ↗
- 2026-06-15ECVita Jukne · Cabinet of Commissioner Jessika RoswallPFAS clean-up High Level dialoguesource ↗
- 2026-06-15ECJessika Roswall · Cabinet of Commissioner Jessika RoswallPFAS clean-up High Level dialoguesource ↗
- UWWTDsource ↗
- 2026-06-10ECKarolina Tomaszewska-Boillot · Cabinet of Commissioner Olivér VárhelyiHealth industry roundtablesource ↗
- 2026-06-10ECLaszlo Kristoffy · Cabinet of Commissioner Olivér VárhelyiHealth industry roundtablesource ↗
- 2026-06-10ECLaszlo Andrejko · Cabinet of Commissioner Olivér VárhelyiHealth industry roundtablesource ↗
- 2026-06-10ECOlivér Várhelyi · Cabinet of Commissioner Olivér VárhelyiHealth industry roundtablesource ↗
- 2026-06-10ECJana Dabbelt · Cabinet of Commissioner Olivér VárhelyiHealth industry roundtablesource ↗
- 2026-06-04ECOlga Solomon · Head of UnitImplementation of the new EU pharmaceutical legislationsource ↗
- Health Policysource ↗
- 2026-05-22ECPatrick Child · Deputy Director-GeneralExtended Producer Responsibility under the recast Urban Wastewater Treatment Directivesource ↗
- 2026-05-20ECPeter Berz · Head of UnitIn his mission letter Commissioner Maroš Šefčovič is tasked to “closely monitor the full enforcement of our trade agreements on market access and rules […]”.source ↗
- 2026-05-20ECDenis Redonnet · Deputy Director-GeneralIn his mission letter Commissioner Maroš Šefčovič is tasked to “closely monitor the full enforcement of our trade agreements on market access and rules […]”.source ↗
- Digital Omnibussource ↗
- 2026-05-12ECRainer Becker · DirectorExchange of views on work in IHIsource ↗
- Hosting the Conference "Promoting Early Detection for Better Cardiovascular Outcomes: Towards Comprehensive Health Check Programmes Across Europe"source ↗
- 2026-05-04ECMartin Seychell · Deputy Director-GeneralExchange of views on the EU global health approach, local manufacturing agenda and role of the EU pharmaceutical industry.source ↗
- Biotech Act expert briefing sessionsource ↗
- Biotechsource ↗
- Cardiovascular Health Policy and Innovation in the EUsource ↗
- Schorzenia sercowo naczyniowe w UEsource ↗
- 2026-04-21ECKarolina Tomaszewska-Boillot · Cabinet of Commissioner Olivér VárhelyiCurrent pharma affairssource ↗
- 2026-04-21ECLaszlo Kristoffy · Cabinet of Commissioner Olivér VárhelyiCurrent pharma affairssource ↗
- 2026-04-21ECLaszlo Andrejko · Cabinet of Commissioner Olivér VárhelyiCurrent pharma affairssource ↗
- 2026-04-21ECOlivér Várhelyi · Cabinet of Commissioner Olivér VárhelyiCurrent pharma affairssource ↗
- 2026-04-21ECJana Dabbelt · Cabinet of Commissioner Olivér VárhelyiCurrent pharma affairssource ↗
- 2026-04-16ECKatri Teedumäe · Cabinet of Commissioner Olivér VárhelyiHealth industry roundtablesource ↗
- 2026-04-16ECJana Dabbelt · Cabinet of Commissioner Olivér VárhelyiHealth industry roundtablesource ↗
- 2026-04-16ECKarolina Tomaszewska-Boillot · Cabinet of Commissioner Olivér VárhelyiHealth industry roundtablesource ↗
- 2026-04-16ECOlivér Várhelyi · Cabinet of Commissioner Olivér VárhelyiHealth industry roundtablesource ↗
- 2026-04-16ECLaszlo Andrejko · Cabinet of Commissioner Olivér VárhelyiHealth industry roundtablesource ↗
- 2026-04-16ECLaszlo Kristoffy · Cabinet of Commissioner Olivér VárhelyiHealth industry roundtablesource ↗
- Biotech Actsource ↗
- Biotech Actsource ↗
- Urban Waste Water Directive - Resolutionsource ↗
- Digital Omnibussource ↗
- EU Health Policysource ↗
- 2026-03-26ECNils Behrndt · Deputy Secretary-GeneralCurrent context of pharmaceutical production in the EU and major challengessource ↗
- Biotech actsource ↗
- 2026-03-25ECStéphane Séjourné · Cabinet of Executive Vice-President Stéphane SéjournéInternational context of the pharmaceutical industrysource ↗
- 2026-03-25ECEstelle Goeger · Cabinet of Executive Vice-President Stéphane SéjournéInternational context of the pharmaceutical industrysource ↗
- 2026-03-25ECAnna Nykiel-Mateo · Cabinet of Executive Vice-President Stéphane SéjournéInternational context of the pharmaceutical industrysource ↗
- Biotech Actsource ↗
- Biotech Act Isource ↗
- Politischer Austauschsource ↗
- 2026-03-19ECMarc Lemaitre · Director-GeneralNext generation of European public-private partnerships under FP10 / Horizon Europesource ↗
- MDR/IVDRsource ↗
- EBCP reportsource ↗
- Health Policysource ↗
Frequently asked
How many EU lobbying meetings has European Federation of Pharmaceutical Industries and Associations disclosed?
European Federation of Pharmaceutical Industries and Associations (EU Transparency Register no. 38526121292-88) appears in 274 disclosed meetings with EU officials and MEPs between 2019-04-23 and 2026-09-18: 186 with the European Commission and 88 with Members of the European Parliament.
What does European Federation of Pharmaceutical Industries and Associations lobby on?
European Federation of Pharmaceutical Industries and Associations's disclosed EU meetings most often concern Health, Trade, Technology, Social. Every meeting and its topic is listed with its official source on this page.
Who does European Federation of Pharmaceutical Industries and Associations meet in Brussels?
Across its disclosed meetings, European Federation of Pharmaceutical Industries and Associations has met Commission officials including Stella Kyriakides, Olivér Várhelyi, Thierry Breton, and MEPs including JARUBAS Adam, WÖLKEN Tiemo, ANDRIUKAITIS Vytenis Povilas. These are counts of officially disclosed meetings, not a measure of influence.
Primary sources
Every meeting above is a public disclosure by the European Commission or a Member of the European Parliament; counts are of disclosed meetings only and are not a measure of influence. Methodology. Data © European Union (Decision 2011/833/EU) & the European Parliament.
Related on the graph
The same footprint, mapped onto the topics and files it touches.
Get the EU lobbying brief
We’ll email you when major new lobbying meetings are disclosed — free, no account, built from public EU data with every entry cited. We only email on real updates.
See your company’s overlap with European Federation of Pharmaceutical Industries and Associations — and the rest of the corpus.
Enter your company and Lex builds a cited Exposure Map in about 30 seconds. Free, no login.